Table 2.

Mean/proportion of the measures of adherence over time, by category of drug

Drug category	Adherence measure	Baseline	Month 2	Month 4	Month 6
DRV (3 participants)	SRA Proportion	66.67	66.67*	100	100
	PCA Mean	nc	87.12	98.23	89.96
	PDC Mean	nc	93.85	98.33	83.33
	HDC† Mean (Range)	2.99 (2.48–3.94)	3.82 (3.15–4.43)	4.74 (3.40–5.66)	3.65 (2.35–4.36)
DTG (16 participants)	SRA Proportion	93.75	75.00	87.50	68.75
	PCA Mean	nc	91.17	88.94	93.56
	PDC Mean	nc	90.32	87.87	89.70
	HDC† Mean (Range)	1.89 (0–5.75)	1.75 (0–4.26)	2.00 (0.49–4.39)	1.57 (0.26–2.94)
FTC (48 participants)	SRA Proportion	93.75	83.33	77.08‡	87.23
	PCA Mean	nc	91.45	90.44	87.86
	PDC Mean	nc	93.03	91.22	89.88
	HDC† Mean (Range)	0.91 (0–7.58)	0.82 (0–3.25)	0.85 (0–3.55)	1.05¶ (0–3.51)
TDF (24 participants)	SRA Proportion	87.50	76.19	75.00	85.00
	PCA Mean	nc	95.05	95.25	93.87
	PDC Mean	nc	90.53	96.69	85.85
	HDC† Mean (Range)	0.07 (0.02–0.24)	0.06 (0.02–0.16)	0.06** (0.01–0.16)	0.06** (0.01–0.15)

For SRA, the proportion of participants who reported excellent or very good adherence is reported. For the remaining measures, the mean is reported

DRV darunavir, DTG dolutegravir, FTC emtricitabine, HDC hair drug concentration, nc not calculated, PCA pill count adherence, PDC proportion of days covered, SRA self-rated adherence, TDF tenofovir disoproxil fumarate

^*No p value calculated due to lack of discordant pairs

^†

For HDC, the unit is ng/mg and the limits of quantification of the tests are as follows:

Drug	Lower Limit of Quantification	Higher Limit of Quantification
TDF	0.0020	0.40
FTC	0.0200	4.00
DRV	0.0400	20.00
DTG	0.0200	20.00

^‡p-value < 0.05 for McNemar’s exact test with baseline value

^**p-value < 0.05 for Sign test with baseline value